New approaches to pathogenetic therapy of patients suffering with tuberculosis and viral hepatitis C

Purpose of the study. The study of the effectiveness of the domestic hepatoprotector “Remaxol” in the complex treatment of patients with pulmonary tuberculosis in combination with CHC on the background of drug and alcoholic liver damage. Materials and methods. 108 patient histories with diagnosis of pulmonary tuberculosis were analyzed, in which chronic hepatitis C (CHC) was defined as a concomitant pathology. The average age of the patients was 36.4 ± 10.5 years. Patients of the first group (n = 37) with a diagnosis of pulmonary tuberculosis in combination with CHC on the background of chronic alcohol intoxication received complex chemotherapy for tuberculosis, and as a pathogenetic therapy, Remaxol was intravenously dripped 400 ml once a day for 12 days. The comparison group (n = 23) with the same diagnosis were on complex antituberculous chemotherapy in combination with pathogenetic and symptomatic therapy. Patients of the second group (n = 25) with a diagnosis of pulmonary tuberculosis against the background of CHC in combination with drug damage to the liver received a complex chemotherapy for tuberculosis, as well as a Remaxol intravenous drip 400 ml once a day for 12 days in quality of pathogenetic therapy. Patients of the control group (n = 23) with the same diagnosis were on complex antituberculous chemotherapy in combination with pathogenetic and symptomatic therapy. Results. Infusion therapy with the drug “Remaxol” led to the rapid disappearance of dyspeptic disorders and pain syndrome, a significant decrease in cytolysis. The pronounced hepatotropic effect of the drug “Remaxol” was confirmed by the rates of decrease in the average indices of ALT and total bilirubin. The conclusion. The use of hepatoprotector “Remaxol” in the complex treatment of patients with pulmonary tuberculosis with concomitant pathology of HCV on the background of alcohol and drug damage contributes to the improvement of the functional state of the liver.

туберкулез, вирусный гепатит С, патогенетическая терапия, ремаксол, гепатотропный эффект, tuberculosis, viral hepatitis C, pathogenetic therapy, “Remaxol”, hepatotropic effect